Novo Nordisk: renal failure trial halted
(CercleFinance.com) - Novo Nordisk has announced the discontinuation of the FLOW trial, evaluating the effects of its once-weekly injectable semaglutide, versus placebo, on the progression of renal failure in patients with type 2 diabetes or chronic kidney disease.
This decision was based on a recommendation from the independent data monitoring committee, which concluded that the results of an interim analysis met certain predefined criteria for stopping the trial prematurely on grounds of efficacy.
The process of closing the trial will therefore be launched. To protect the trial's integrity, Novo Nordisk will not know its results until the end of the trial. It expects FLOW results to be released in H1 2024.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This decision was based on a recommendation from the independent data monitoring committee, which concluded that the results of an interim analysis met certain predefined criteria for stopping the trial prematurely on grounds of efficacy.
The process of closing the trial will therefore be launched. To protect the trial's integrity, Novo Nordisk will not know its results until the end of the trial. It expects FLOW results to be released in H1 2024.
Copyright (c) 2023 CercleFinance.com. All rights reserved.